I

Infinity Dermatology NYC | Forest Hills Dermatology Group

Research site

(Unclaimed)

Location

80-02 Kew GaRoadens Road, Suite 107, Kew Gardens, New York, United States of America

Site insights

Top conditions

Top treatments

Rocatinlimab

PF-04965842

Risankizumab

Upadacitinib

AMG 451

Dupilumab

BMS-986165

Deucravacitinib

Ruxolitinib

RPT193

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 31 total trials

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis (ADAPTIVE)

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Enrolling

Atopic Dermatitis

Atopic Dermatitis Eczema

Drug: Placebo

Drug: IMG-007

A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

This is a Phase 3 multicenter, double-blind study to evaluate the safety and efficacy of vehicle-controlled topical MOB015B in the treatment of Dista...

Active, not recruiting

Onychomycosis

Drug: MOB015B

Drug: Vehicle (Placebo Comparator)

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Enrolling

Plaque Psoriasis

Drug: Ustekinumab

Drug: Deucravacitinib

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (ATLANTIS)

This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).The purpose of thi...

Active, not recruiting

Dermatitis Atopic

Drug: Amlitelimab